UP 269-6

structure given in first source; angiotensin receptor antagonist

Also Known As:

5-methyl-7-n-propyl-8-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-(1,2,4)-triazolo(1,5-c)pyrimidin-2(3H)-one; UP-269-6

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Tetrazoles: 14
      - UP 269-6: 3
  - Pyrimidines: 510
    - UP 269-6: 3

Related Diseases

1.	Hypertrophy 02/01/1997 - "8. In conclusion, UP 269-6 was shown to be a potent antiproliferative agent both in vitro on AII-induced hyperplasia and hypertrophy of VSMC derived from normotensive and hypertensive rats, and in vivo upon intimal thickening induced by carotid artery balloon injury in the rat." 02/01/1997 - "1. The present studies were designed to measure the affinity of UP 269-6, a newly developed angiotensin AT1 receptor antagonist, for vascular AT1 receptors from normotensive and hypertensive rats and to investigate in vitro, its effects on angiotensin II (AII)-induced hyperplasia and hypertrophy of vascular smooth muscle cells (VSMC). "
2.	Hyperplasia 02/01/1997 - "8. In conclusion, UP 269-6 was shown to be a potent antiproliferative agent both in vitro on AII-induced hyperplasia and hypertrophy of VSMC derived from normotensive and hypertensive rats, and in vivo upon intimal thickening induced by carotid artery balloon injury in the rat." 02/01/1997 - "1. The present studies were designed to measure the affinity of UP 269-6, a newly developed angiotensin AT1 receptor antagonist, for vascular AT1 receptors from normotensive and hypertensive rats and to investigate in vitro, its effects on angiotensin II (AII)-induced hyperplasia and hypertrophy of vascular smooth muscle cells (VSMC). "
3.	Neointima 02/01/1997 - "7. UP 269-6 (75 mg kg-1 day-1) administered orally in the diet for 20 days induced a 38% reduction in neointimal area and a 36% reduction in neointima/media ratio associated with the intimal thickening induced by carotid artery balloon injury. "
4.	Hypotension (Low Blood Pressure) 09/15/1995 - "Furthermore, UP 269-6 did not induce hypotension and did not cause alteration in heart rate and ECG waveforms in dogs even at a dose 1000 times higher than the angiotensin II antagonistic effective dose. "
5.	Dizziness (Lightheadedness) 06/01/1995 - "Dizziness and light-headedness on standing were reported after UP 269-6 at higher doses. "

Related Drugs and Biologics

1.	Angiotensin II
2.	Type 1 Angiotensin Receptor